186A South Street 
Boston, MA 02111 
(617) 423-0650 
COMMITTEE FOR RESPONSIBLE GENETICS 
March 26, 1986 
Advisory Board 
Nicholas Ashford. Ph.O. 
Hull* Balrd-Bimay. M.S. 
Roy L. Birrwt 
Jonathan Beckwith. Ph.O. 
Philip Baraano, J.O.' 
Eula Bingham. Ph.O. 
Oavid Brower 
Llab* Cavaliarl. Ph.O." 
Jotaph Colllna. Ph.O. 
Oonald Comb. Ph.O. 
Barry CommoMr, Ph.O. 
Molly Coy*. M.D. 
Osvid Ehranlald. Ph.O.. M.O. 
Email Englandar. Ph.O. 
Rich Englar 
Sam Epstein. Ph.O. 
Richard Falk. J.O. 
Rota Faldbarg. Ph.O. 
Marcut Faldman, Ph.O. 
Cary Fowlar 
(.oil Gibbs 
Tarri Goldberg" 
Richard Goldstein. Ph.O. 
Slephan Jay Gould. Ph.O. 
Colin Gracey* 
Eric Holtzman. Ph.O. 
•h Hubbard. Ph.O." 
ton Jcnsan 
4ihan King. Ph.O." 
Sheldon Krimsky, Ph.O." 
Mare Lappa. Ph.O." 
Marvin Lagalor. Ph.O. 
Bruce Levin. Ph.O. 
Richard Lavins, Ph.O. 
Richard Lawonlin. Ph.O. 
Manning Marable. Ph.O. 
Anthony Mazzocchi* 
Evarail Mendelsohn. Ph.O. 
Albert Mayarhoff, J.O. 
Clair* Nader. Ph.O." 
Slush Newman, Ph.O." 
Oavid Noble. Ph.O. 
Judy Norsigian 
Richard Novick, Ph.O. 
Christina Oliver. M.O. 
David Ozonofl. M.O. 
Scon Paradis* 
Oavid Pimentel. Ph.O. 
Bernard Rapoport 
Barbara Rosenberg. Ph.O." 
Barbara Katz Rothman. Ph.O. 
Roger Shinn 
Victor Sldel. M.O. 
Helen Rodriguez-Trlas. M.O. 
John Vandermeer, Ph.O. 
George Wald. Ph.O. Nobel Lauraal* 
William Winpisinger 
Slav* Wodka 
Sidney Wolle. M.O. 
Susan Wright, Ph.O." 
"Esecullve Council 
Nachama L. Wilker 
Eseculiv* Otfdor 
William J. Cartland 
Director, Office of Recombinant 
DMA Activities 
Building 31, Room 3B10 
National Institutes of Health 
Bethesda, Maryland 20205 
(f) Dear Dr. Cartland: 
With proposals for human genetic therapy expected to be submitted 
to the RAC in the near future, the Committee for Responsible 
Genetics (CRG) believes it is necessary to define now, in advance, 
the types of gene therapy that will be considered and to rule out, 
categorically, those that would not be in the public Interest. We 
therefore propose an amendment to the NIH Guidelines, the wording 
of which is attached. In support of this amendment we submit the 
enclosed rationale, and request that it be published in the Federal 
Register together with the proposed amendment. 
Although the "Points to Consider" document, prepared by the RAC, 
states that germ-line therapy proposals will not be entertained 
by the RAC at present, it also states that the document will be 
frequently revised. We therefore believe that the restrictive 
provisions belong in the more permanent parent Guidelines rather 
than under "Points to Consider." 
Please let us know when the RAC will take up this proposal. 
[ 68 ] 
Recombinant DNA Research, Volume 1 1 
